AIRS trades 8.9% above Wall Street's consensus target of $4.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes AIRS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, AirSculpt Technologies, Inc. (AIRS) has a Wall Street consensus price target of $4.50, based on estimates from 5 covering analysts. With the stock currently trading at $4.94, this represents a potential downside of -8.9%. The company has a market capitalization of $348M.
Analyst price targets range from a low of $4.50 to a high of $4.50, representing a 0% spread in expectations. The median target of $4.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, AIRS trades at a trailing P/E of -26.0x. Analysts expect EPS to grow +72.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SKINThe Beauty Health Company | $86M | $0.66 | $1.53 | +130.8% | Hold | — | 14 |
INMDInMode Ltd. | $849M | $13.40 | $18.00 | +34.3% | Hold | 10.0x | 11 |
SSKNSTRATA Skin Sciences, Inc. | $806683 | $0.14 | — | — | — | — | — |
ESTAEstablishment Labs Holdings Inc. | $2.5B | $84.81 | $86.00 | +1.4% | Buy | — | 14 |
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
SYKStryker Corporation | $117.9B | $307.80 | $387.46 | +25.9% | Buy | 20.5x | 51 |
ISRGIntuitive Surgical, Inc. | $144.5B | $406.78 | $597.78 | +47.0% | Buy | 38.9x | 55 |
ABTAbbott Laboratories | $153.7B | $88.38 | $127.46 | +44.2% | Buy | 16.1x | 41 |
ZBHZimmer Biomet Holdings, Inc. | $17.2B | $87.97 | $96.33 | +9.5% | Hold | 10.4x | 42 |
LPGDorian LPG Ltd. | $1.7B | $39.56 | $55.00 | +39.0% | Hold | 9.2x | 9 |
Quick answers to the most common questions about buying AIRS stock.
Wall Street's consensus price target for AIRS is $4.5, -8.9% from its current price of $4.94. The below-market target from 5 analysts suggests limited near-term appreciation.
AIRS has a consensus rating of "Hold" based on 5 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $4.5 implies -8.9% downside from current levels.
AIRS's current price is $4.94 with a consensus target of $4.5 (-8.9% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $4.5 for AIRS, while the most conservative target is $4.5. The consensus of $4.5 represents the median expectation. These targets typically reflect 12-month expectations.
AIRS is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AIRS stock forecast based on 5 Wall Street analysts shows a consensus price target of $4.5, with estimates ranging from $4.5 (bear case) to $4.5 (bull case). The median consensus rating is "Hold".
Analysts are cautious on AIRS, with 0 Sell ratings and a price target of $4.5 (-8.9% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AIRS analyst price targets range from $4.5 to $4.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.